Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Recommendation of “Reduce” by Brokerages

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have earned an average rating of “Reduce” from the twenty analysts that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, seventeen have issued a hold recommendation and one has given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $13.76.

Several research firms have recently issued reports on SAGE. Scotiabank decreased their target price on Sage Therapeutics from $19.00 to $17.00 and set a “sector outperform” rating for the company in a research report on Thursday, July 25th. The Goldman Sachs Group decreased their target price on Sage Therapeutics from $19.00 to $11.00 and set a “neutral” rating for the company in a research report on Friday, July 26th. HC Wainwright restated a “neutral” rating and set a $25.00 target price on shares of Sage Therapeutics in a research report on Wednesday. JPMorgan Chase & Co. decreased their target price on Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating for the company in a research report on Tuesday, August 6th. Finally, Wedbush decreased their target price on Sage Therapeutics from $9.00 to $8.00 and set a “neutral” rating for the company in a research report on Wednesday.

Institutional Investors Weigh In On Sage Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Sage Therapeutics by 8.1% in the 1st quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock valued at $107,781,000 after acquiring an additional 432,013 shares during the period. RTW Investments LP raised its stake in Sage Therapeutics by 0.9% in the 4th quarter. RTW Investments LP now owns 5,197,019 shares of the biopharmaceutical company’s stock valued at $112,619,000 after acquiring an additional 47,537 shares during the period. Bellevue Group AG raised its stake in Sage Therapeutics by 27.1% in the 1st quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock valued at $83,684,000 after acquiring an additional 952,193 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Sage Therapeutics by 69.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock valued at $15,217,000 after acquiring an additional 333,805 shares during the period. Finally, Federated Hermes Inc. bought a new stake in Sage Therapeutics in the 2nd quarter valued at $7,281,000. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Stock Down 1.8 %

Sage Therapeutics stock opened at $6.37 on Friday. The stock has a 50-day simple moving average of $7.74 and a 200 day simple moving average of $10.99. Sage Therapeutics has a 12-month low of $5.84 and a 12-month high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.02). The firm had revenue of $8.65 million during the quarter, compared to analyst estimates of $8.85 million. Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. Sage Therapeutics’s revenue for the quarter was up 249.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($2.68) earnings per share. Sell-side analysts anticipate that Sage Therapeutics will post -6.47 EPS for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.